Literature DB >> 17002511

Are nonhuman primates good models for SARS?

Robert J Hogan.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 17002511      PMCID: PMC1576335          DOI: 10.1371/journal.pmed.0030411

Source DB:  PubMed          Journal:  PLoS Med        ISSN: 1549-1277            Impact factor:   11.069


× No keyword cloud information.
I would like to respond to Haagmans and Osterhaus' Perspective [1] on Lawler et al.’s study [2]. I have been actively studying SARS virus both in vitro and in numerous animal models including mice, cotton rats, ferrets, and macaques since April, 2003 (about six weeks after the virus was first identified). While I do concur with some of the statements made by Haagmans and Osterhaus, I am compelled to provide an alternative view. I completely agree with the stance that an animal model which mimics the severe disease observed in human cases is needed. However, the continued use of nonhuman primates in these studies is simply not warranted. Indeed, multiple groups have tried unsuccessfully to reproduce this model, including Lawler and colleagues [2] . For example, I attended the WHO meeting on SARS in Rotterdam in February, 2004, at which Steven Jones, of the National Microbiology Laboratory, Winnipeg, Canada, said: “If I were one of those monkeys, maybe I’d just take a Tylenol” [3]. With my colleagues, I conducted a study in which both rhesus and cynomolgus macaques were infected with SARS-CoV. I did not see any clinical signs of disease or marked lung pathology [4]. A study by Subbarao and colleagues had similar findings: “SARS coronavirus (SARS-CoV) administered intranasally and intratracheally to rhesus, cynomolgus and African Green monkeys (AGM) replicated in the respiratory tract but did not induce illness” [5]. Perhaps the most interesting issue is that Lawler and colleagues clearly state that “SARS-CoV infection of cynomolgus macaques did not reproduce the severe illness seen in the majority of adult human cases of SARS” [2]. To my knowledge, only Osterhaus’s laboratory and laboratories from China have reported severe disease in SARS-CoV infected macaques. Osterhaus mentions that the variability in results may be due to factors such as the strain of virus used, and this is certainly true. However, he has not released the virus isolate used in these studies to me or my colleagues in spite of requests. Given that so many groups (e.g., the Centers for Disease Control and Prevention, the United States Army Medical Research Institute of Infectious Diseases, the National Institute of Allergy and Infectious Diseases, etc.) with excellent scientific skills and credentials have reported contradictory results with at least two strains of SARS-CoV, it is troublesome that the use of nonhuman primates in SARS pathogenesis, vaccine, and therapeutic testing continues.
  5 in total

1.  Medicine. Caution urged on SARS vaccines.

Authors:  Eliot Marshall; Martin Enserink
Journal:  Science       Date:  2004-02-13       Impact factor: 47.728

2.  Macaque model for severe acute respiratory syndrome.

Authors:  Thomas Rowe; Guangping Gao; Robert J Hogan; Ronald G Crystal; Thomas G Voss; Rebecca L Grant; Peter Bell; Gary P Kobinger; Nelson A Wivel; James M Wilson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

3.  Nonhuman primate models for SARS.

Authors:  Bart L Haagmans; Albert D M E Osterhaus
Journal:  PLoS Med       Date:  2006-04-18       Impact factor: 11.069

4.  Cynomolgus macaque as an animal model for severe acute respiratory syndrome.

Authors:  James V Lawler; Timothy P Endy; Lisa E Hensley; Aura Garrison; Elizabeth A Fritz; May Lesar; Ralph S Baric; David A Kulesh; David A Norwood; Leonard P Wasieloski; Melanie P Ulrich; Tom R Slezak; Elizabeth Vitalis; John W Huggins; Peter B Jahrling; Jason Paragas
Journal:  PLoS Med       Date:  2006-04-18       Impact factor: 11.069

5.  Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.

Authors:  Josephine McAuliffe; Leatrice Vogel; Anjeanette Roberts; Gary Fahle; Steven Fischer; Wun-Ju Shieh; Emily Butler; Sherif Zaki; Marisa St Claire; Brian Murphy; Kanta Subbarao
Journal:  Virology       Date:  2004-12-05       Impact factor: 3.616

  5 in total
  6 in total

1.  Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2020-09-18       Impact factor: 2.829

Review 2.  From Genetics to Epigenetics: Top 4 Aspects for Improved SARS-CoV-2 Vaccine Designs as Paradigmatic Examples.

Authors:  Darja Kanduc
Journal:  Glob Med Genet       Date:  2021-11-09

3.  T cell responses to whole SARS coronavirus in humans.

Authors:  Chris Ka-fai Li; Hao Wu; Huiping Yan; Shiwu Ma; Lili Wang; Mingxia Zhang; Xiaoping Tang; Nigel J Temperton; Robin A Weiss; Jason M Brenchley; Daniel C Douek; Juthathip Mongkolsapaya; Bac-Hai Tran; Chen-lung Steve Lin; Gavin R Screaton; Jin-lin Hou; Andrew J McMichael; Xiao-Ning Xu
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

4.  A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung.

Authors:  Yongxiong Chen; Vera Sau-Fong Chan; Bojian Zheng; Kelvin Yuen-Kwong Chan; Xiaoning Xu; Leo Yuk-Fai To; Fang-Ping Huang; Ui-Soon Khoo; Chen-Lung Steve Lin
Journal:  J Exp Med       Date:  2007-10-08       Impact factor: 14.307

5.  The flaws and human harms of animal experimentation.

Authors:  Aysha Akhtar
Journal:  Camb Q Healthc Ethics       Date:  2015-10       Impact factor: 1.284

6.  Medical, Genomic, and Evolutionary Aspects of the Peptide Sharing between Pathogens, Primates, and Humans.

Authors:  Darja Kanduc; Yehuda Shoenfeld
Journal:  Glob Med Genet       Date:  2020-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.